Posters

Partial List of 2015 Poster Titles

  • Academia Sinica: Quantitation of Core-Fucosylation on N-Glycan of the Antibodies
  • Affibody AB: A Novel Affinity Resin for the Purification of Albumod Half-Life Extended Biopharmaceuticals
  • Agency for Science, Technology and Research (A*STAR): Enhanced Antigen Detection in Immunohistochemical (IHC) Staining Using a "Digitised" Chimeric Antibody
  • Agency for Science, Technology and Research (A*STAR): Targeting RON for Therapy
  • AIT Austrian Institute of Technology GmbH: scFv-Fc Fusion-Protein Microarrays for Fast Detection of Methicillin-Resistant Staphylococcus aureus
  • Ajinomoto Co., Inc.: Site-Specific Protein Conjugation with Corynex® Expression Technology
  • Ajinomoto Co., Inc.: Corynex®: A Gram-Positive Microbial Protein Secretion System That Delivers Better Results
  • Anti-Doping Laboratory Qatar: Mast Cell Proteases as Key Clinical Markers and New Targets for Drug Development in Allergic Disease: Implications for Anti-Doping Policy
  • Anti-Doping Laboratory Qatar: Production of Novel Variants of Superantigens for Cancer Treatment
  • Apogenix GmbH: Hexavalent TNF-Receptor Ligands for Cancer Treatment and Immune Modulation: TRAIL, CD40L and Beyond
  • AptaIT GmbH: Next-Generation Analysis of Deep Sequencing Data: Bringing Light into the Black Box of Phage Display Experiments
  • Astellas Pharma, Inc.: High Resolution Antibody Modeling Identifies “Design-able” Antibody
  • Bio-Rad AbD Serotec GmbH: Recombinant Anti-Idiotypic Antibodies for Antibody Drug Development
  • Bruker Daltonik GmbH: Upstream Quality Control of Therapeutic Antibodies Using Automated IdeS Digestion and Subunit Separation in Combination with Ultrahigh-Resolution QTOF Analysis
  • Bruker Daltonik GmbH: Automatic De Novo Identification and Profiling of Disulfide Bonds in Biopharmaceuticals
  • CALIXAR: Stabilization of Native and Functional Membrane Proteins: CALIXAR Approach
  • CALIXAR: Native Isolation of Functional Ion Channels: CALIXAR Approach
  • Center for Genetic Engineering and Biotechnology: Elution by pH Change in the Hydrophobic Interaction Chromatography for Purification of a Virus-Like Particle (VLP)
  • Centre National de la Recherche Scientifique (CNRS): A High-Throughput Method Based on Flow Cytometry for the Screening of Phage-scFvs for the Theranostic of Atherosclerosis
  • Chemical Computing Group: Generating Focused Protein and Antibody Libraries for Protein Engineering
  • Chemical Computing Group: New Approach for Detection and Visualization of Aggregation-Prone Regions
  • Chinese University of Hong Kong: Anti-Idiotype scFv for Pharmacokinetics Determination in Phase I/II Clinical Trials
  • CSL Limited: Novel One-Step Cloning Method for Rapid Reformatting of Phage-Displayed Antibody Fragments into Full Length IgGs
  • Development Center for Biotechnology: Application of Single Peripheral Blood B Cells for Fully Human Monoclonal Antibodies Screening
  • Development Center for Biotechnology: Light Chain-Bridged Single Chain Anti-Her2/Anti-CD3 Bi-Specific Antibody for Her2+ Cancer Therapy
  • Development Center for Biotechnology: Pre-Clinical PK-PD Analysis of Anti-HSV mAb in Disease Animals
  • Dublin City University: Rapid, Single-Step Characterisation of Monoclonal scFv Pools from an Avian Phage Library Raised and Enriched Against Prostate Cancer
  • Dublin City University: Development of an Autonomous, In-Situ, Point-of-Need System for Monitoring Harmful Algae Species Azadinium spinosum and Azaspiracid
  • EPFL Lausanne: Selection of Monobodies Interfering with Cancer Signaling
  • ETH Zurich: Immunocytokines for the Treatment of Ulcerative Colitis
  • Fairjourney Biologics: Highly Versatile Tool Box for Generation of Monoclonal Antibodies Against Different Domains and Epitopes of Soluble and Membrane Targets
  • Fairjourney Biologics: Generation and Validation of Naïve Libraries as an Immunization-Free Source of Diverse Panels of Specific Human Fabs and Llama Singles Domain Antibodies
  • FFE Service GmbH: Three Novel Protocols for Protein Purification by Free-Flow-Electrophoresis
  • Fraunhofer Institute for Cell Therapy and Immunology (IZI): Cell-Free Synthesis Meets Antibody Production: Eukaryotic Cell-Free Systems as Novel Source of Antibody Fragments
  • Freeslate, Inc.: Evaluation of an Automated Process for Formulation Screening
  • Garvan Institute of Medical Research: Generation and Characterization of a G-Quadruplex Nucleic Acids Specific Single Domain Antibody
  • GEK Srl: Food-Specific IgG Antibodies: Evaluation of Dried Blood Collection Devices Using the ELISA Assay
  • Genedata AG: NGS-Based Cell Line Selection and Genome Knowledge Management
  • Genedata AG: Engineering Next-Generation Biotherapeutics: Developability and Manufacturability
  • Genedata AG: New Workflow System for the Design and Evaluation of Antibody Drug Conjugates (ADCs)
  • Genedata AG: Integrated System for Automated Cell Line Development, Including Use of Ambr Online Data
  • Genedata AG: Deconvolution of Intact Mass Spectra as a Tool to Measure Payloads of Cytotoxic Drugs Linked to Monoclonal Antibodies
  • Genedata AG: Mass Spectrometry Software for the Modern Biopharma Enterprise
  • HiFiBiO SAS: Antibody Discovery by Deep Mining of Immune Repertoires: A Demonstration of the HiFiBiO CelliGO™ Platform Versatility and Robustness with Tetanus Toxoid Antigen as a Case Study
  • HiFiBiO SAS: Antibody Discovery by Deep Mining of Immune Repertoires: Application of the HiFiBiO CelliGO™ Platform for the Discovery of Next-Generation Antibody Antibiotics
  • Horiba Scientific: Antibodies Screening by Surface Plasmon Resonance Imaging
  • iBET - Instituto de Biologia Experimental e Tecnológica: A Minimal Delta-Like 1 Functional Unit as a Tool for Notch Pathway Activation and Generation of Anti-DLL1 Antibody
  • iBET - Instituto de Biologia Experimental e Tecnológica: Development of AAV-shRNA Vectors to Target Human Basal-Like Breast Cancer
  • IIB-Sant Pau (Biomedical Research Institute Sant Pau): Regulatable Self-Assembling of In Vivo Stable Protein Nanoparticles Using Non-Amyloidogenic Peptide Tags
  • Immunocore Ltd.: IMCgp100 ImmTAC: Targeting Malignant Melanoma with High Affinity T-Cell Receptors
  • Industrial Technology Research Institute: Preclinical ADC Pharmacokinetics Workflow in ITRI
  • IntelliCyt Corporation: High Throughput Cytokine Secretion Assays for Functional Characterization of Checkpoint Inhibitors
  • Isogenica Ltd.: LlamdA: A Powerful System for the Discovery of Synthetic VHH Antibodies
  • Jagiellonian University: Highly Stable IgG3-Based Reagent for Typing of B Antigen from ABO Blood Group System
  • Japan Advanced Institute Science and Technology: New Insights of Engineering Expression Systems Based on Ultrafast DNA and RNA Photo-Cross-Linking
  • Kaneka Pharma Europe NV: Performance and Application of PUREfrex 2.0 with Increased Productivity
  • Kobe University: Streptavidin Hydrogel as a Scaffold for Protein Assembly
  • Kobe University: C-Terminal-Oriented Immobilization of Enzymes Using Sortase A-Mediated Technique
  • KTH - Royal Institute of Technology: Development of Affinity Domains for Site Specific Labelling of IgG
  • KTH - Royal Institute of Technology: Structural Epitope Mapping of Eculizumab Using Cell Surface Display Allows Better Stratification of Responders
  • Kumamoto University: Stabilization of Proteins Encapsulated in Injectable Polypseudorotaxane Hydrogels
  • LEITAT Technological Center: Recombinant Antibodies for Research, Diagnosis and Therapy
  • Medigen Biotechnology Corporation: A Novel Human Native mAb Against Pandemic H1N1 Virus
  • MedImmune Ltd.: Ultra-High Content Screening of Cell-Surface-Selected Antibodies in a Complex 3D Tumour Cell Model
  • Moscow State University: Novel Bi-Promoter Expression System for the Production of Recombinant IgG Antibodies
  • MSD: Comparison of SAFC Culture Medium Produced at Two SAFC Sites Using a Qualified Small Scale Bioreactor Model
  • MSD: Strategy to Cross-Verify Light Obscuration with Orthogonal Technique, Microflow Imaging
  • NovImmune SA: Targeting the Macrophage Checkpoint CD47 with an Effective Yet Safe Format
  • Novo Nordisk A/S: Unmasking Translucent Protein Particles by Improved MFIT Algorithms
  • Novo Nordisk Pharmatech: Particle Identification by Multi-Technique Methods at Novo Nordisk Pharmatech
  • Novozymes Biopharma UK Ltd.: Veltis® Engineered Albumins for Optimized Serum Half-Life Extension
  • PhyNexus, Inc.: Fully Automated Mini, Midi, and Maxi Plasmid Prep on the AutoPlasmid MEA Instrument
  • Polyplus-transfection SA: Improving Productivity in Transient Gene Expression Systems with FectoPRO™, a Novel Powerful Transfection Solution
  • PolyTherics Ltd., an Abzena Company: New Generation of Stable and Homogeneous Antibody Drug Conjugates with Improved In Vivo Efficacy
  • Promega Corporation: Fc Effector Function Reporter Bioassays for Rapid and Quantitative Measurement of ADCC and ADCP Mechanisms of Action
  • Promega Corporation: Immune Checkpoint and Immunostimulatory Reporter Bioassays to Advance the Development of Therapeutic Antibodies in Immunotherapy Research Programs
  • Promega Corporation: IdeZ: An IgG-Cleaving Protease from Streptococcus equi with Improved Activity Towards Mouse IgG Molecules
  • Protagen Protein Services GmbH: Analytical Support in Cell Line- and Process Development for Achieving Biosimilarity
  • ProteoNic BV: Optimization of 2G UNicT Technology for Enhanced Protein Production Under GS Selection in CHO-S and CHO GS -/- Cells
  • Proteros Biostructures GmbH: Enhancing Development of Biotherapeutics: Technology Application Examples
  • RIKEN Center for Sustainable Resource Science: Secretory Production of Tetrameric Native Full-Length Streptavidin with Thermostability Using Streptomyces Lividans as a Host
  • Roche Diagnostics GmbH: Cell Line Development Platform for Asymmetric 2+1 CrossMab Bispecific Antibodies
  • Roche NimbleGen: Single Amino Acid Resolution of Antibody Epitopes and Complete Human Proteome Cross-Reactivity Analysis Using Ultra High Density Tiling Peptide Microarrays
  • SOLVE Research and Consultancy AB: AF4 and SEC as Tools for Protein Aggregation Studies
  • Technical University of Denmark: Engineering the CHO Cell
  • Terumo Corporation: Evalation of Antibody–Poly(Amino Acid) Complexes: Preparation of High-Concentration Antibody Formulations and Their Pharmaceutical Properties
  • TSI, Inc.: Investigating Protein Fragments and Aggregates as Well as Protein-Protein Interactions Using Macroion Mobility Spectrometry
  • TTP Labtech Ltd.: A New Approach to Run Target- and Phenotypic -Based Antibody Screening to Identify Better Therapeutic Antibodies
  • Universidade de Lisboa: Cellection - Intracellular Targeted Evolution for Discovery of Therapeutic Antibodies
  • Universidade de Lisboa: Nanobody-Based Specific Delivery of Therapeutic Molecules Against HIV Infection
  • Universidade de Lisboa: Development of Highly Specific and Potent Antibody Drug Conjugated Compounds for Treatment of B-Cell Malignancies
  • Universitat Autònoma de Barcelona: Downstream CD44-Targeted Protein Nanoparticles Purification from Bacteria Influences Protein Stability, Functionality and In Vivo Biodistribution
  • University College Dublin: Engineering Improved mAb Affinity Capture with Nanomaterials
  • University College Dublin: Protein Retriever PRO: An Efficient Scalable Nanoscale Affinity Purification System
  • University College Dublin: Optimisation of Biosensor Surface Immobilisation and Display Using a Novel EF Hand Based Affinity Tag
  • University College Dublin: Development of the Novel EF-Tag Platform for High Throughput Screening of Novel Protein Binders
  • University College London: Pyridazinediones: A Novel Class of Tuneable Reagents for the Selective Dual Modification of Proteins
  • University College London: Next Generation Maleimides: A New Class of Reagent for Protein Modification
  • University of Aveiro: Aqueous Biphasic Systems Composed of Cholinium-Based Ionic Liquids for the Extraction of Immunoglobulin Y, IgY, from Egg Yolk
  • University of Borås: Textile Bioreactor for Ethanol Production
  • University of Coimbra: IgY-Technology Revisited
  • University of Helsinki: Enhanced Soluble Expression of Human Ciliary Neurotrophic Factor in Escherichia coli
  • University of Queensland: Monoclonal Antibodies Against Canine Cell Surface Receptor c-Kit, Isolated from a Phage Display Library Using Whole Cell Panning
  • University of Queensland: Assay for Simultaneous Detection of Dengue Virus Serotypes
  • University of Queensland: Targeted Delivery of Nanomedicines Using Bispecific Antibodies
  • University of Tampere: Brave New Avidins
  • University of Tübingen: Immunocytokines Comprising Mutated IL-15 Induce Target Cell Restricted NK Cell Activation
  • University of Tübingen: Development of Recombinant Bispecific Antibodies for Selective Stimulation of the CD95 Death Receptor on Activated B Cells and Lymphoma Cells
  • University of Tübingen: Use of Blocking-Reagents for Reducing Specific Bispecific Antibody Induced Off-Target T Cell Activation
  • University of Tübingen: Characterization and Comparison of Two PSMA x CD3 Bispecific Formats
  • University of Zurich: Establishment of an Innovative High-Throughput Platform for Next-Generation Binder Discovery
  • University of Zurich: Engineering Proteins for Cytosolic Delivery
  • Vaccinex, Inc.: Antibody Library Display on a Mammalian Virus: Combining the Advantages of Panning and Cell Sorting in One Technology
  • VECT-HORUS S.A.S.: Design of Peptide-Based Vectors That Target LDLR Mediated Transport for Drug Delivery to the CNS and Other Organs
  • VTT Technical Research Centre of Finland: Next Generation Biotherapeutic Production System: The Filamentous Fungus Trichoderma reesei
  • Waters Corporation: Complementary HILIC-Based Separations for the Characterization and Analysis of Erythropoetin
  • Wroclaw University of Technology: Generation of IgY Antibodies Specific to Selected ENOX2 Epitopes

PRESENT A POSTER AND SAVE €45!  

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by 2 October 2015.

Register online, or by phone, fax or mail.  Please indicate that you would like to present a poster.  Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract using our online abstract submission tool.  Please see below for more information. 

Reasons you should present your research poster at this conference: 

  • Your research will be seen by our international delegation, representing leaders from
    top pharmaceutical, biotech, academic and government institutions
  • Receive €45 off your registration
  • Your poster abstract will be published in our conference materials

  

 NOTE: Special poster restrictions. 

 

 1. Posters will be limited to ONE poster per person.  

 

 2. You must select the ONE TRACK at which you wish to present your poster. Your poster will hang only for the duration of that track.  (Your poster selection must be concurrent with your registration selection, but it does not have to be the same.)   * If necessary, posters may be reassigned to another session based on attendance.   


 3. Special poster size required:   Posters should be portrait (vertical) orientation, ISO paper size A0: (841 mm wide x 1189 mm high) or (33.11 inches wide × 46.81 inches high).  Maximum board dimensions are (1000 mm wide x 1200 mm high) or (39.37 inches wide × 47.24 inches high).  Oversize posters will not fit.

 

* CHI reserves the right to publish your poster title and abstract in various marketing materials and products. 


Click here for poster instructions and guidelines 

Inquiries: jring@healthtech.com